Quantcast

Latest MorphoSys Stories

2014-06-24 12:28:56

LONDON and BOSTON, June 24, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that its President, Dan Grau, will present a company overview at the JMP Securities Healthcare Conference (24-25 June 2014, New York, NY, USA). His presentation will take place on 25 June at 9.30 am EDT. For a full list of events at which Heptares will be present, please visit http://www.heptares.com About...

2014-06-10 16:27:52

LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Antibody Partnering Terms and Agreementshttp://www.reportbuyer.com/countries/north_america/usa/antibody_partnering_terms_agreements.html The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.The Antibody Partnering Terms and...

2014-05-29 04:22:16

LONDON and BOSTON, May 29, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Malcolm Weir, Heptares' Chief Executive Officer and co-founder, will give a company presentation at the Jefferies 2014 Global Healthcare in New York City, NY, USA. The presentation will take place at 9:00am EDT on Monday 2 June. In addition, Heptares will give presentations at the following industry and scientific...

2014-05-07 08:32:47

MONROVIA, Calif., May 7, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release first quarter financial results after market close on Wednesday, May 14, 2014. Xencor management will host a webcast and conference call the same day at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss the financial...

2014-04-16 04:22:10

LONDON, April 16, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Dan Grau, Heptares' President, will be attending two upcoming industry partnering and investment conferences. Mr Grau will attend the 9th Annual Neurotech Investing & Partnering Conference [https://www.regonline.com/builder/site/default.aspx?EventID=1246370 ] in Boston, MA, USA (23-24 April 2014) at which he will...

2014-03-27 12:29:43

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/3xxp4l/global ) has announced the addition of the "Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Innovations have contributed to the availability of a range of new treatments for diseases resulting in improvements in the length and quality of life and reduced disease burden for...

2014-03-26 08:22:56

DUBLIN, Mar. 26, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/lnx8jm/treating ) has announced the addition of the "Concise Analysis on Treating Refractory Hematological Malignancies for Multiple Myeloma" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) "Concise Analysis on Treating Refractory Hematological Malignancies for Multiple Myeloma", provides an overview of the therapies for Multiple Myeloma (Newly...

2014-03-26 04:21:13

LONDON and BOSTON, March 26, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that a company presentation to be given by its Chief Executive Officer, Malcolm Weir, at BioCentury Future Leaders in the Biotech Industry [https://www.biocentury.com/conferences/futureleaders/dates ] on 28 March 2014 will be webcast live. The presentation will take place at 9.30am ET in room 302/303 at the Millennium Broadway...

2014-03-19 16:23:41

Conference call to be held today at 4:30 p.m. EDT MONROVIA, Calif., March 19, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2013 and provided a review of business highlights. "We are very pleased that Xencor now has five clinical...

2014-03-13 08:28:48

MONROVIA, Calif., March 13, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and full year 2013 financial results after market close on Wednesday, March 19, 2014. Xencor management will host a webcast and conference call the same day at 4:30 p.m. EDT (1:30 p.m. PDT) to...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related